Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07138755 | The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients | PHASE2 | RECRUITING | 35 | — | — | Aug 29, 2025 | Sep 1, 2030 | Mar 25, 2026 | 1 | China |
The time from the beginning of treatment to the time when the disease progresses or the patient dies from any cause
| Arm | Type | Description |
|---|---|---|
| adaptive radiotherapy strategy | EXPERIMENTAL | After two cycles of sintilimab and platinum based chemotherapy, receive two additional courses of sintilimab and platinum based chemotherapy and adaptive radiotherapy strategy |
| Name | Type | Description |
|---|---|---|
| Experimental | DRUG | Drug: Sintilimab, 200mg IV D1 Q3W, Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5 D1 IV Q3W, Paclitaxel or Paclitaxel liposome 135-175mg/m2 D1 IV Q3W(Squamous） Drug: Sintilimab, 200mg IV D1 Q3W, Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5 D1 IV Q3W, Pemetrexed, 500mg/m2 D1 IV Q3W(adenocarcinoma） Radiation:Adaptive radiotherapy with V20\<20%: 1.PGTV60-66Gy/2.0-2.2Gy/30F;PTV54Gy/1.8Gy/30F;2.PGTV54-66Gy/2.0-2.2Gy/30F；3.PGTV50Gy/2.0Gy/25F |
Inclusion Criteria: 1. The subjects are willing and able to comply with the scheduled visits, treatment plans, laboratory tests, and other requirements of the study 2. Age range of 18-75 years old upon enrollment, both male and female are eligible 3. Stage III NSCLC confirmed by histology or cytolo...